Latest news with #Wakim
Business Insider
09-05-2025
- Business
- Business Insider
Neuren Pharmaceuticals Limited (NURPF) Receives a Buy from Bell Potter
Bell Potter analyst Thomas Wakim maintained a Buy rating on Neuren Pharmaceuticals Limited (NURPF – Research Report) today and set a price target of A$20.00. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wakim is an analyst with an average return of -6.9% and a 40.00% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Clinuvel Pharmaceuticals , and Opthea . In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a A$27.90 price target. The company has a one-year high of $15.43 and a one-year low of $5.41. Currently, Neuren Pharmaceuticals Limited has an average volume of 1,176.
Business Insider
07-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA) and Immutep Ltd (OtherPRRUF)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on BioAge Labs, Inc. (BIOA – Research Report) and Immutep Ltd (PRRUF – Research Report). Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. BioAge Labs, Inc. (BIOA) In a report released today, Andy Hsieh from William Blair reiterated a Hold rating on BioAge Labs, Inc.. The company's shares closed last Tuesday at $3.95, close to its 52-week low of $3.80. According to Hsieh is a 4-star analyst with an average return of 6.0% and a 43.7% success rate. Hsieh covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Barinthus Biotherapeutics, and Corbus Pharmaceuticals. BioAge Labs, Inc. has an analyst consensus of Hold, with a price target consensus of $5.67. Immutep Ltd (PRRUF) In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Immutep Ltd, with a price target of A$0.70. The company's shares closed last Monday at $0.22. According to Wakim is a 1-star analyst with an average return of -6.9% and a 40.0% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Neuren Pharmaceuticals Limited, Clinuvel Pharmaceuticals, and Opthea. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Immutep Ltd with a $0.98 average price target.
Arabian Business
06-05-2025
- Business
- Arabian Business
Bloom Holding launches phase two of Granada Apartments in Abu Dhabi
Bloom Holding, a leading UAE real estate development company, announced the launch of the second phase of 'Granada', its premium community living apartments in Abu Dhabi. Sales will commence for the apartments, located within Bloom Living, at the second phase with prices starting from AED630,000 and attractive post-handover payment plans available, the company said. Inspired by the aesthetic of traditional Mediterranean homes and elevated by the comfort of modern living, the second phase of Granada will feature a variety of residential apartment units across eight luxury, low-rise four-story buildings. The second phase of the project is scheduled to be completed in Q1 2028. This premium apartment community is fully equipped to cater to all types of residents and all age groups, making it a true multi-generational destination, the company said. Carlos Wakim, CEO of Bloom Holding, said the launch of Granada 's second phase builds on the remarkable success of Bloom Living' previously launched phases. 'The overwhelming response, which we have witnessed so far, highlights the strong interest in our premium integrated community living concept, and we are confident that this phase will achieve similar success,' he said. Wakim said Bloom Living is a master planned community strategically located within Abu Dhabi – a city that offers a booming economy, a robust tourism industry, and a reliable market, making it an irresistible destination for real estate investors seeking lucrative opportunities and high rental yields. 'The emirate offers world-class infrastructure, and we believe that any investment in Abu Dhabi is an investment in the future,' he said.
Business Insider
01-05-2025
- Business
- Business Insider
Bell Potter Sticks to Its Buy Rating for Genetic Signatures Ltd. (GSS)
In a report released today, Thomas Wakim from Bell Potter maintained a Buy rating on Genetic Signatures Ltd. (GSS – Research Report), with a price target of A$0.75. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wakim is an analyst with an average return of -13.4% and a 23.08% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Opthea , Clinuvel Pharmaceuticals , and CSL. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Genetic Signatures Ltd. with a A$1.05 average price target. Based on Genetic Signatures Ltd.'s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$8.5 million and a GAAP net loss of A$15.2 million. In comparison, last year the company earned a revenue of A$3.6 million and had a GAAP net loss of A$10.47 million
Business Insider
30-04-2025
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for PYC Therapeutics Limited (PYC)
Bell Potter analyst Thomas Wakim maintained a Buy rating on PYC Therapeutics Limited (PYC – Research Report) today and set a price target of A$2.30. Protect Your Portfolio Against Market Uncertainty Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter. Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox. According to TipRanks, Wakim is an analyst with an average return of -13.4% and a 23.08% success rate. Wakim covers the Healthcare sector, focusing on stocks such as Opthea , Clinuvel Pharmaceuticals , and CSL. Currently, the analyst consensus on PYC Therapeutics Limited is a Strong Buy with an average price target of A$3.35.
